- €12.09bn
- €12.39bn
- €3.67bn
- 93
- 13
- 94
- 78
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 22.93 | ||
PEG Ratio (f) | 1.8 | ||
EPS Growth (f) | 14.58% | ||
Dividend Yield (f) | 1.01% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.13 | ||
Price to Tang. Book | 4.61 | ||
Price to Free Cashflow | 77.29 | ||
Price to Sales | 3.18 | ||
EV to EBITDA | 15 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 12.03% | ||
Return on Equity | 10.98% | ||
Operating Margin | 13.65% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | 2,674.8 | 3,118.2 | 3,376.2 | 3,589.1 | 3,674.7 | 3,944.57 | 4,227.2 | 8.7% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +5.99 | +48.43 | +47.98 | -24.39 | -20.64 | +34.14 | +11.83 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Directors
- Alexandre Merieux CHM (47)
- Guillaume Bouhours CFO (45)
- Pierre Boulud COO
- Valerie Leylde EVP
- Francois Lacoste EVP
- Mark Miller EVP
- Yasha Mitrotti EVP
- Esther Wick EVP
- Randy Rasmussen EVP
- Pierre Charbonnier VPR (54)
- Philippe Archinard DRC (61)
- Jean-Luc Belingard DRC (72)
- Frederic Beseme DRC (64)
- Harold Boel IND (56)
- Marie-Helene Habert IND (56)
- Marie-Paule Kieny IND (66)
- Agnes Lemarchand IND (66)
- Fanny Letier IND (42)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 1st, 1967
- Public Since
- June 7th, 2004
- No. of Employees
- 14,651
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 117,929,352
- Address
- 376, chemin de l'Orme, CRAPONNE, 69280
- Web
- https://www.biomerieux.fr/
- Phone
- +33 478872000
- Auditors
- Ernst & Young et Autres
Latest News for BIM
Upcoming Events for BIM
Full Year 2024 Biomerieux SA Earnings Release
Similar to BIM
AbL Diagnostics SA
Euronext - Paris
Affluent Medical SAS
Euronext - Paris
Alpha MOS SA
Euronext - Paris
Amplitude Surgical SA
Euronext - Paris
Aton SA
Euronext - Paris
FAQ
As of Today at 18:37 UTC, shares in Biomerieux SA are trading at €102.50. This share price information is delayed by 15 minutes.
Shares in Biomerieux SA last closed at €102.50 and the price had moved by +10.62% over the past 365 days. In terms of relative price strength the Biomerieux SA share price has underperformed the FTSE Global All Cap Index by -3.98% over the past year.
The overall consensus recommendation for Biomerieux SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Biomerieux SA dividend yield is 0.83% based on the trailing twelve month period.
Last year, Biomerieux SA paid a total dividend of €0.85, and it currently has a trailing dividend yield of 0.83%. We do not have any data on when Biomerieux SA is to next pay dividends.
We do not have data on when Biomerieux SA is to next pay dividends. The historic dividend yield on Biomerieux SA shares is currently 0.83%.
To buy shares in Biomerieux SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €102.50, shares in Biomerieux SA had a market capitalisation of €12.09bn.
Here are the trading details for Biomerieux SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: BIM
Based on an overall assessment of its quality, value and momentum Biomerieux SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biomerieux SA is €118.80. That is 15.9% above the last closing price of €102.50.
Analysts covering Biomerieux SA currently have a consensus Earnings Per Share (EPS) forecast of €4.07 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomerieux SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +3.14%.
As of the last closing price of €102.50, shares in Biomerieux SA were trading +2.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biomerieux SA PE ratio based on its reported earnings over the past 12 months is 22.93. The shares last closed at €102.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biomerieux SA's management team is headed by:
- Alexandre Merieux - CHM
- Guillaume Bouhours - CFO
- Pierre Boulud - COO
- Valerie Leylde - EVP
- Francois Lacoste - EVP
- Mark Miller - EVP
- Yasha Mitrotti - EVP
- Esther Wick - EVP
- Randy Rasmussen - EVP
- Pierre Charbonnier - VPR
- Philippe Archinard - DRC
- Jean-Luc Belingard - DRC
- Frederic Beseme - DRC
- Harold Boel - IND
- Marie-Helene Habert - IND
- Marie-Paule Kieny - IND
- Agnes Lemarchand - IND
- Fanny Letier - IND